BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32101575)

  • 21. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1.
    Jia B; Liu W; Gu J; Wang J; Lv W; Zhang W; Hao Q; Pang Z; Mu N; Zhang W; Guo Q
    Exp Cell Res; 2019 Feb; 375(1):73-81. PubMed ID: 30586549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1.
    Gallitto M; Cheng He R; Inocencio JF; Wang H; Zhang Y; Deikus G; Wasserman I; Strahl M; Smith M; Sebra R; Yong RL
    J Neurooncol; 2020 May; 147(3):557-566. PubMed ID: 32193690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
    Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
    Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
    Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
    Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
    Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
    Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma.
    Rabé M; Dumont S; Álvarez-Arenas A; Janati H; Belmonte-Beitia J; Calvo GF; Thibault-Carpentier C; Séry Q; Chauvin C; Joalland N; Briand F; Blandin S; Scotet E; Pecqueur C; Clairambault J; Oliver L; Perez-Garcia V; Nadaradjane A; Cartron PF; Gratas C; Vallette FM
    Cell Death Dis; 2020 Jan; 11(1):19. PubMed ID: 31907355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
    Shang C; Tang W; Pan C; Hu X; Hong Y
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long intergenic noncoding RNA 00021 promotes glioblastoma temozolomide resistance by epigenetically silencing p21 through Notch pathway.
    Zhang S; Guo S; Liang C; Lian M
    IUBMB Life; 2020 Aug; 72(8):1747-1756. PubMed ID: 32449315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets.
    Chien CH; Chuang JY; Yang ST; Yang WB; Chen PY; Hsu TI; Huang CY; Lo WL; Yang KY; Liu MS; Chu JM; Chung PH; Liu JJ; Chou SW; Chen SH; Chang KY
    J Biomed Sci; 2019 Oct; 26(1):77. PubMed ID: 31629402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gamabufotalin induces a negative feedback loop connecting ATP1A3 expression and the AQP4 pathway to promote temozolomide sensitivity in glioblastoma cells by targeting the amino acid Thr794.
    Lan YL; Chen C; Wang X; Lou JC; Xing JS; Zou S; Hu JL; Lyu W; Zhang B
    Cell Prolif; 2020 Jan; 53(1):e12732. PubMed ID: 31746080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
    Liang H; Chen Z; Sun L
    Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells.
    Wang H; Ren S; Xu Y; Miao W; Huang X; Qu Z; Li J; Liu X; Kong P
    Anticancer Drugs; 2019 Jan; 30(1):81-88. PubMed ID: 30273182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.